⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL297724 | 0.67 | — | — | |
| SCHEMBL974207 | 0.67 | — | — | |
| SCHEMBL335098 | 0.65 | — | — | |
| SCHEMBL2008710 | 0.62 | — | — | |
| SCHEMBL27207651 | 0.61 | DYRK1A (0.43) | — | |
| SCHEMBL29672799 | 0.61 | — | — | |
| SCHEMBL3262556 | 0.61 | — | — | |
| SCHEMBL334805 | 0.61 | — | — | |
| SCHEMBL13112244 | 0.60 | KDM4E (0.40) | — | |
| SCHEMBL7446199 | 0.57 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 224 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220287748-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR SPINAL MUSCULAR ATROPHY | REBORNA BIOSCIENCES, INC. (JP) | 2022-09-15 | — | — | US | claimed |
| EP-3816160-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR SPINAL MUSCULAR ATROPHY | Reborna Biosciences, Inc. (JP) | 2021-05-05 | — | — | EP | claimed |
| EP-2922828-B1 | 4,6-DIAMINO-PYRIMIDINE DERIVATIVES AS BMI-1 INHIBITORS FOR TREATING CANCER | PTC THERAPEUTICS INC (US) | 2020-07-08 | — | — | EP | claimed |
| US-10584115-B2 | Substituted pyridine and pyrazine BMI-1 inhibitors | PTC THERAPEUTICS, INC. (US) | 2020-03-10 | — | — | US | claimed |
| EP-3039015-B1 | SUBSTITUTED PYRIMIDINE BMI-1 INHIBITORS | PTC THERAPEUTICS INC (US) | 2019-10-30 | — | — | EP | claimed |
| US-10428050-B2 | Substituted reverse pyrimidine Bmi-1 inhibitors | PTC THERAPEUTICS, INC. (US) | 2019-10-01 | — | — | US | claimed |
| US-10370371-B2 | Substituted pyrimidine Bmi-1 inhibitors | PTC THERAPEUTICS, INC. (US) | 2019-08-06 | — | — | US | claimed |
| US-9975878-B2 | Substituted triazine BMI-1 inhibitors | PTC THERAPEUTICS, INC. (US) | 2018-05-22 | — | — | US | claimed |
| US-20160297798-A1 | SUBSTITUTED TRIAZINE BMI-1 INHIBITORS | PTC THERAPEUTICS, INC. | 2016-10-13 | — | — | US | claimed |
| US-20160280685-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS | PTC THERAPEUTICS, INC. | 2016-09-29 | — | — | US | claimed |
| EP-3071553-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS | PTC Therapeutics, Inc. (US) | 2016-09-28 | — | — | EP | claimed |
| US-20160214978-A1 | SUBSTITUTED PYRIMIDINE BMI-1 INHIBITORS | PTC THERAPEUTICS, INC. | 2016-07-28 | — | — | US | claimed |
| EP-3039015-A1 | SUBSTITUTED PYRIMIDINE BMI-1 INHIBITORS | PTC Therapeutics, Inc. (US) | 2016-07-06 | — | — | EP | claimed |
| US-20150315182-A1 | SUBSTITUTED REVERSE PYRIMIDINE BMI-1 INHIBITORS | PTC THERAPEUTICS, INC. | 2015-11-05 | — | — | US | claimed |
| EP-2922828-A2 | SUBSTITUTED REVERSE PYRIMIDINE BMI-1 INHIBITORS | PTC Therapeutics, Inc. (US) | 2015-09-30 | — | — | EP | claimed |
| WO-2015076800-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS | PTC THERAPEUTICS, INC. (US) | 2015-05-28 | — | — | WO | claimed |
| WO-2015076801-A1 | SUBSTITUTED TRIAZINE BMI-1 INHIBITORS | PTC THERAPEUTICS, INC. (US) | 2015-05-28 | — | — | WO | claimed |
| WO-2015030847-A1 | SUBSTITUTED PYRIMIDINE BMI-1 INHIBITORS | PTC THERAPEUTICS, INC. (US) | 2015-03-05 | — | — | WO | claimed |
| WO-2014081906-A2 | SUBSTITUTED REVERSE PYRIMIDINE BMI-1 INHIBITORS | PTC THERAPEUTICS, INC. (US) | 2014-05-30 | — | — | WO | claimed |
| EP-4392414-A1 | INHIBITORS OF NLRP3 | PTC Therapeutics, Inc. (US) | 2024-07-03 | — | — | EP | disclosed |
| US-12012410-B2 | Substituted pyrazolo[1,5-a]pyrazines for spinal muscular atrophy | REBORNA BIOSCIENCES, INC. (JP) | 2024-06-18 | — | — | US | disclosed |
| EP-4334319-A1 | 2,8-DIHYDROPYRAZOLO[3,4-B]INDOLE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | Merck Patent GmbH (DE) | 2024-03-13 | — | — | EP | disclosed |
| US-11771088-B2 | Insecticidal compositions and methods | MONSANTO TECHNOLOGY LLC (US) | 2023-10-03 | — | — | US | disclosed |
| US-20230278958-A1 | TRICYCLIC HETEROCYCLES | MERCK PATENT GMBH (DE) | 2023-09-07 | — | — | US | disclosed |
| US-20230227460-A1 | FUSED AZA-HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD (CN) | 2023-07-20 | — | — | US | disclosed |
| US-11702646-B2 | Methods for modulating RNA splicing | PTC THERAPEUTICS, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-20230183239-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF | ABBVIE INC (US) | 2023-06-15 | — | — | US | disclosed |
| US-20230174538-A1 | Tricyclic heterocycles | MERCK PATENT GMBH (DE) | 2023-06-08 | — | — | US | disclosed |
| EP-4185564-A1 | TRICYCLIC HETEROCYCLES | Merck Patent GmbH (DE) | 2023-05-31 | — | — | EP | disclosed |
| US-20230144197-A1 | 4-[[(7-AMINOPYRAZOLO[1,5-A]PYRIMIDIN-5-YL)AMINO]METHYL]PIPERIDIN-3-OL COMPOUNDS AND THEIR THERAPEUTIC USE | Carrick Therapeutics Limited (IE) | 2023-05-11 | — | — | US | disclosed |
| WO-2023028534-A1 | INHIBITORS OF NLRP3 | PTC THERAPEUTICS, INC. (US) | 2023-03-02 | — | — | WO | disclosed |
| US-11547703-B2 | Substituted fused heteroaromatic tricyclic compounds as kinase inhibitors and the use thereof | Impact Therapeutics (Shanghai), Inc (CN) | 2023-01-10 | — | — | US | disclosed |
| US-20220287748-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR SPINAL MUSCULAR ATROPHY | REBORNA BIOSCIENCES, INC. (JP) | 2022-09-15 | — | — | US | disclosed |
| WO-2022128850-A1 | NOVEL ISOQUINOLINE DERIVATIVES AND PHARMACEUTICAL COPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES | GALAPAGOS NV (BE) | 2022-06-23 | — | — | WO | disclosed |
| US-20220064150-A1 | SUBSTITUTED REVERSE PYRIMIDINE BMI-1 INHIBITORS | PTC THERAPEUTICS INC (US) | 2022-03-03 | — | — | US | disclosed |
| US-11180483-B2 | Substituted reverse pyrimidine Bmi-1 inhibitors | PTC THERAPEUTICS, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| US-20210128535-A1 | Substituted Fused Heteroaromatic Tricyclic Compounds as Kinase Inhibitors and The Use Thereof | IMPACT THERAPEUTICS, INC. (CN) | 2021-05-06 | — | — | US | disclosed |
| EP-3816160-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR SPINAL MUSCULAR ATROPHY | Reborna Biosciences, Inc. (JP) | 2021-05-05 | — | — | EP | disclosed |
| US-20210070747-A1 | 2(1H)-QUINOLINONE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2021-03-11 | — | — | US | disclosed |
| EP-3775186-A1 | ECTONUCLEOTIDE PYROPHOSPHATE-PHOSPHODIESTERASE (ENPP) CONJUGATES AND USES THEREOF | AbbVie Inc. (US) | 2021-02-17 | — | — | EP | disclosed |
| US-20210030001-A1 | INSECTICIDAL COMPOSITIONS AND METHODS | MONSANTO TECHNOLOGY LLC (US) | 2021-02-04 | — | — | US | disclosed |
| US-20210023234-A1 | ECTONUCLEOTIDE PYROPHOSPHATE-PHOSPHODIESTERASE (ENPP) CONJUGATES AND USES THEREOF | ABBVIE INC (US) | 2021-01-28 | — | — | US | disclosed |
| US-20200291024-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF | ABBVIE INC (US) | 2020-09-17 | — | — | US | disclosed |
| EP-3676254-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF | AbbVie Inc. (US) | 2020-07-08 | — | — | EP | disclosed |
| EP-2922828-B1 | 4,6-DIAMINO-PYRIMIDINE DERIVATIVES AS BMI-1 INHIBITORS FOR TREATING CANCER | PTC THERAPEUTICS INC (US) | 2020-07-08 | — | — | EP | disclosed |
| US-10584115-B2 | Substituted pyridine and pyrazine BMI-1 inhibitors | PTC THERAPEUTICS, INC. (US) | 2020-03-10 | — | — | US | disclosed |
| EP-3604281-A1 | 2(1H)-QUINOLINONE DERIVATIVE | Taisho Pharmaceutical Co., Ltd. (JP) | 2020-02-05 | — | — | EP | disclosed |
| US-20190330615-A1 | METHODS FOR MODULATING RNA SPLICING | PTC THERAPEUTICS, INC. (US) | 2019-10-31 | — | — | US | disclosed |
| EP-3039015-B1 | SUBSTITUTED PYRIMIDINE BMI-1 INHIBITORS | PTC THERAPEUTICS INC (US) | 2019-10-30 | — | — | EP | disclosed |
| WO-2019191504-A1 | ECTONUCLEOTIDE PYROPHOSPHATE-PHOSPHODIESTERASE (ENPP) CONJUGATES AND USES THEREOF | MAVUPHARMA, INC. (US) | 2019-10-03 | — | — | WO | disclosed |
| US-10428050-B2 | Substituted reverse pyrimidine Bmi-1 inhibitors | PTC THERAPEUTICS, INC. (US) | 2019-10-01 | — | — | US | disclosed |
| US-20190282703-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE (ENPP) CONJUGATES AND USES THEREOF | ABBVIE INC. | 2019-09-19 | — | — | US | disclosed |
| EP-3252045-B1 | CYANOGUANIDINES AND THEIR USE AS ANTIVIRAL AGENTS | ABBVIE INC (US) | 2019-09-04 | — | — | EP | disclosed |
| WO-2019154366-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 江苏奥赛康药业有限公司 | 2019-08-15 | — | — | WO | disclosed |
| US-10370371-B2 | Substituted pyrimidine Bmi-1 inhibitors | PTC THERAPEUTICS, INC. (US) | 2019-08-06 | — | — | US | disclosed |
| US-10308605-B2 | Proton pump inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-06-04 | — | — | US | disclosed |
| US-10233179-B2 | Thiazoles and uses thereof | ABBVIE INC. (US) | 2019-03-19 | — | — | US | disclosed |
| WO-2019046778-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF | MAVUPHARMA, INC. (US) | 2019-03-07 | — | — | WO | disclosed |
| US-10112911-B2 | Substituted cyanoguanidines as oral anti-virals | ABBVIE INC. (US) | 2018-10-30 | — | — | US | disclosed |
| EP-2516420-B1 | AMINOALKYLPYRIMIDINE DERIVATIVES AS HISTAMINE H4 RECEPTOR ANTAGONISTS | MEDICIS PHARMACEUTICAL CORP (US) | 2018-08-22 | — | — | EP | disclosed |
| US-9975878-B2 | Substituted triazine BMI-1 inhibitors | PTC THERAPEUTICS, INC. (US) | 2018-05-22 | — | — | US | disclosed |
| US-9907306-B2 | Compositions and methods for controlling nematode pests | MONSANTO TECHNOLOGY LLC (US) | 2018-03-06 | — | — | US | disclosed |
| US-9873702-B2 | Heterocyclic compounds as biogenic amine transport modulators | SOUTHERN RESEARCH INSTITUTE (US) | 2018-01-23 | — | — | US | disclosed |
| EP-2867221-B1 | CYANOGUANIDINES AND THEIR SUE AS ANTIVIRAL AGENTS. | ABBVIE INC (US) | 2018-01-17 | — | — | EP | disclosed |
| EP-3252045-A1 | CYANOGUANIDINES AND THEIR USE AS ANTIVIRAL AGENTS | AbbVie Inc. (US) | 2017-12-06 | — | — | EP | disclosed |
| EP-2836486-B1 | DIAMINOPYRIMIDINES USEFUL AS INHIBITORS OF THE HUMAN RESPIRATORY SYNCYTIAL VIRUS (RSV) | ABBVIE INC (US) | 2017-10-04 | — | — | EP | disclosed |
| US-20170152247-A1 | COMPOSITIONS AND METHODS FOR CONTROLLING NEMATODES | MONSANTO TECHNOLOGY LLC (US) | 2017-06-01 | — | — | US | disclosed |
| EP-2493895-B1 | N-CONTAINING HETEROARYL DERIVATIVES AS JAK3 KINASE INHIBITORS | VECTURA LTD (GB) | 2017-04-26 | — | — | EP | disclosed |
| US-9567355-B2 | Hepatitis C inhibitors and uses thereof | ABBVIE INC. (US) | 2017-02-14 | — | — | US | disclosed |
| US-20160355530-A1 | HEPATITIS C INHIBITORS AND USES THEREOF | ABBVIE INC. | 2016-12-08 | — | — | US | disclosed |
| US-9499477-B2 | Hydroxamic acid derivative | TOYAMA CHEMICAL CO., LTD. (JP) | 2016-11-22 | — | — | US | disclosed |
| US-20160297798-A1 | SUBSTITUTED TRIAZINE BMI-1 INHIBITORS | PTC THERAPEUTICS, INC. | 2016-10-13 | — | — | US | disclosed |
| US-20160280685-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS | PTC THERAPEUTICS, INC. | 2016-09-29 | — | — | US | disclosed |
| EP-3071553-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS | PTC Therapeutics, Inc. (US) | 2016-09-28 | — | — | EP | disclosed |
| US-9453007-B2 | Hepatitis C inhibitors and uses thereof | ABBVIE INC. (US) | 2016-09-27 | — | — | US | disclosed |
| US-9447051-B2 | Diaminopyrimidines and uses thereof | ABBVIE INC. (US) | 2016-09-20 | — | — | US | disclosed |
| US-20160227780-A1 | COMPOSITIONS AND METHODS FOR CONTROLLING NEMATODE PESTS | MONSANTO TECHNOLOGY LLC (US) | 2016-08-11 | — | — | US | disclosed |
| US-20160214978-A1 | SUBSTITUTED PYRIMIDINE BMI-1 INHIBITORS | PTC THERAPEUTICS, INC. | 2016-07-28 | — | — | US | disclosed |
| US-9399649-B2 | Compounds for treating spinal muscular atrophy | PTC THERAPEUTICS, INC. (US) | 2016-07-26 | — | — | US | disclosed |
| EP-3039015-A1 | SUBSTITUTED PYRIMIDINE BMI-1 INHIBITORS | PTC Therapeutics, Inc. (US) | 2016-07-06 | — | — | EP | disclosed |
| US-20160159809-A1 | HETEROCYCLIC COMPOUNDS AS BIOGENIC AMINE TRANSPORT MODULATORS | SOUTHERN RESEARCH INSTITUTE | 2016-06-09 | — | — | US | disclosed |
| US-9290460-B2 | 1-(Arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP inhibitors and the use thereof | IMPACT THERAPEUTICS, INC. (CN) | 2016-03-22 | — | — | US | disclosed |
| US-20160068521-A1 | THIAZOLES AND USES THEREOF | ABBVIE INC. | 2016-03-10 | — | — | US | disclosed |
| EP-2988742-A1 | THIAZOLES AND USES THEREOF | AbbVie Inc. (US) | 2016-03-02 | — | — | EP | disclosed |
| EP-2678349-B1 | C-4\" POSITION SUBSTITUTED MACROLIDE DERIVATIVE | TAISHO PHARMACEUTICAL CO LTD (JP) | 2016-01-13 | — | — | EP | disclosed |
| US-20160002213-A1 | HEPATITIS C INHIBITORS AND USES THEREOF | ABBVIE INC. | 2016-01-07 | — | — | US | disclosed |
| US-9186411-B2 | Pharmaceutical composition | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-11-17 | — | — | US | disclosed |
| US-20150322045-A1 | CYANOGUANIDINES AND USES THEREOF | ABBVIE INC. | 2015-11-12 | — | — | US | disclosed |
| US-20150315182-A1 | SUBSTITUTED REVERSE PYRIMIDINE BMI-1 INHIBITORS | PTC THERAPEUTICS, INC. | 2015-11-05 | — | — | US | disclosed |
| US-9173887-B2 | Hepatitis C inhibitors and uses thereof | ABBVIE INC. (US) | 2015-11-03 | — | — | US | disclosed |
| EP-2922828-A2 | SUBSTITUTED REVERSE PYRIMIDINE BMI-1 INHIBITORS | PTC Therapeutics, Inc. (US) | 2015-09-30 | — | — | EP | disclosed |
| US-9139609-B2 | C-4″ position substituted macrolide derivative | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2015-09-22 | — | — | US | disclosed |
| US-20150225335-A1 | NOVEL HYDROXAMIC ACID DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2015-08-13 | — | — | US | disclosed |
| US-9073821-B2 | Hydroxamic acid derivative | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2015-07-07 | — | — | US | disclosed |
| WO-2015076801-A1 | SUBSTITUTED TRIAZINE BMI-1 INHIBITORS | PTC THERAPEUTICS, INC. (US) | 2015-05-28 | — | — | WO | disclosed |
| WO-2015076800-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS | PTC THERAPEUTICS, INC. (US) | 2015-05-28 | — | — | WO | disclosed |
| US-20150126515-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS, INC. (US) | 2015-05-07 | — | — | US | disclosed |
| EP-2867221-A1 | CYANOGUANIDINES AND THEIR USE AS ANTIVIRAL AGENTS | AbbVie Inc. (US) | 2015-05-06 | — | — | EP | disclosed |
| US-20150119380-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | F. HOFFMANN-LA ROCHE AG (CH) | 2015-04-30 | — | — | US | disclosed |
| WO-2015030847-A1 | SUBSTITUTED PYRIMIDINE BMI-1 INHIBITORS | PTC THERAPEUTICS, INC. (US) | 2015-03-05 | — | — | WO | disclosed |
| EP-2836486-A1 | DIAMINOPYRIMIDINES USEFUL AS INHIBITORS OF THE HUMAN RESPIRATORY SYNCYTIAL VIRUS (RSV) | AbbVie Inc. (US) | 2015-02-18 | — | — | EP | disclosed |
| US-8946257-B2 | N-containing heteroaryl derivatives as JAK3 kinase inhibitors | VECTURA LIMITED (GB) | 2015-02-03 | — | — | US | disclosed |
| US-20150025095-A1 | Diaminopyrimidines And Uses Thereof | ABBVIE INC. | 2015-01-22 | — | — | US | disclosed |
| US-20150005232-A1 | INDAZOLE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (US) | 2015-01-01 | — | — | US | disclosed |
| US-8901146-B2 | Aminoalkylpyrimidine derivatives as histamine H4 receptor antagonists | MEDICIS PHARMACEUTICAL CORPORATION (US) | 2014-12-02 | — | — | US | disclosed |
| US-20140349989-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | ALZHEIMER'S INSTITUTE OF AMERICA (US) | 2014-11-27 | — | — | US | disclosed |
| US-20140343070-A1 | PROTON PUMP INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-11-20 | — | — | US | disclosed |
| WO-2014176268-A1 | THIAZOLES AND USES THEREOF | ABBVIE INC. (US) | 2014-10-30 | — | — | WO | disclosed |
| US-20140275711-A1 | 1-(Arylmethyl)-5,6,7,8-tetrahydroquinazolline-2,4-diones and Analogs and the Use Thereof | IMPACT THERAPEUTICS, INC. (CN) | 2014-09-18 | — | — | US | disclosed |
| EP-2327692-B9 | 1-heterocyclylsulfonyl, 2-aminomethyl, 5-(hetero-)aryl substituted 1-H-pyrrole derivatives as acid secretion inhibitors | TAKEDA PHARMACEUTICAL (JP) | 2014-06-04 | — | — | EP | disclosed |
| WO-2014081906-A2 | SUBSTITUTED REVERSE PYRIMIDINE BMI-1 INHIBITORS | PTC THERAPEUTICS, INC. (US) | 2014-05-30 | — | — | WO | disclosed |
| US-20140046043-A1 | C-4\" POSITION SUBSTITUTED MACROLIDE DERIVATIVE | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2014-02-13 | — | — | US | disclosed |
| US-20140038919-A1 | HEPATITIS C INHIBITORS AND USES THEREOF | ABBVIE INC. (US) | 2014-02-06 | — | — | US | disclosed |
| US-20140023642-A1 | 1-(Arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP Inhibitors and the Use Thereof | IMPACT THERAPEUTICS, INC. (CN) | 2014-01-23 | — | — | US | disclosed |
| WO-2014005129-A1 | CYANOGUANIDINES AND THEIR USE AS ANTIVIRAL AGENTS | ABBVIE INC. (US) | 2014-01-03 | — | — | WO | disclosed |
| EP-2678349-A1 | C-4\" POSITION SUBSTITUTED MACROLIDE DERIVATIVE | Taisho Pharmaceutical Co., Ltd. (JP) | 2014-01-01 | — | — | EP | disclosed |
| US-20130289015-A1 | N-CONTAINING HETEROARYL DERIVATIVES AS JAK3 KINASE INHIBITORS | PALAU PHARMA, S.A. | 2013-10-31 | — | — | US | disclosed |
| EP-2655362-A1 | HEPATITIS C INHIBITORS AND USES THEREOF | Abbvie Inc. (US) | 2013-10-30 | — | — | EP | disclosed |
| US-20130261156-A1 | PHARMACEUTICAL COMPOSITION | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-10-03 | — | — | US | disclosed |
| EP-2235016-B1 | AZABICYCLIC CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2013-09-18 | — | — | EP | disclosed |
| WO-2013123401-A1 | DIAMINOPYRIMIDINES USEFUL AS INHIBITORS OF THE HUMAN RESPIRATORY SYNCYTIAL VIRUS (RSV) | ABBVIE INC. (US) | 2013-08-22 | — | — | WO | disclosed |
| US-8501735-B2 | N-containing heteroaryl derivatives as JAK3 kinase inhibitors | PALAU PHARMA, S.A. (ES) | 2013-08-06 | — | — | US | disclosed |
| US-20130131038-A9 | N-CONTAINING HETEROARYL DERIVATIVES AS JAK3 KINASE INHIBITORS | VECTURA LIMITED (GB) | 2013-05-23 | — | — | US | disclosed |
| US-8436187-B2 | 1-heterocyclylsulfonyl, 3-aminomethyl, 5- (hetero-) aryl substituted 1-H-pyrrole derivatives as acid secretion inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-05-07 | — | — | US | disclosed |
| US-8415368-B2 | Acid secretion inhibitor | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-04-09 | — | — | US | disclosed |
| US-20130072677-A1 | NOVEL HYDROXAMIC ACID DERIVATIVE | TOYAMA CHEMICAL CO., LTD. (JP) | 2013-03-21 | — | — | US | disclosed |
| US-8394820-B2 | N-azabicyclic carboxamide derivatives, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2013-03-12 | — | — | US | disclosed |
| EP-2564833-A1 | Photostabilized pharmaceutical composition | Takeda Pharmaceutical Company Limited (JP) | 2013-03-06 | — | — | EP | disclosed |
| EP-2562155-A1 | NOVEL HYDROXAMIC ACID DERIVATIVE | Taisho Pharmaceutical Co., Ltd. (JP) | 2013-02-27 | — | — | EP | disclosed |
| US-20130029942-A1 | COMPOUNDS AND THERAPEUTICAL USES THEREOF | MYREXIS, INC. (US) | 2013-01-31 | — | — | US | disclosed |
| US-20130018031-A1 | AMINOALKYLPYRIMIDINE DERIVATIVES AS HISTAMINE H4 RECEPTOR ANTAGONISTS | MEDICIS PHARMACEUTICAL CORPORATION (US) | 2013-01-17 | — | — | US | disclosed |
| US-20130005965-A1 | ARYL- AND HETEROARYL-SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-03 | — | — | US | disclosed |
| US-20120329786-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | MYREXIS, INC. (US) | 2012-12-27 | — | — | US | disclosed |
| US-8338461-B2 | 1-heterocyclylsulfonyl, 3-aminomethyl, 5-(hetero-)aryl substituted 1-H-pyrrole derivatives as acid secretion inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-12-25 | — | — | US | disclosed |
| US-8338462-B2 | 1-heterocyclylsulfonyl, 3-aminomethyl, 5- (hetero-) aryl substituted 1-H-pyrrole derivatives as acid secretion inhibitors | TAKEDA PHARMACEUTICALS COMPANY LIMITED (JP) | 2012-12-25 | — | — | US | disclosed |
| EP-2516420-A1 | AMINOALKYLPYRIMIDINE DERIVATIVES AS HISTAMINE H4 RECEPTOR ANTAGONISTS | Palau Pharma, S.A. (ES) | 2012-10-31 | — | — | EP | disclosed |
| US-8299035-B2 | 10a-azalide compound having 4-membered ring structure | TAISHO PHARMACEUTUCAL CO., LTD. (JP) | 2012-10-30 | — | — | US | disclosed |
| US-8299261-B2 | 1-heterocyclylsulfonyl, 3-aminomethyl, 5-(hetero-) aryl substituted 1-H-pyrrole derivatives as acid secretion inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-30 | — | — | US | disclosed |
| US-8293715-B2 | 10a-Azalide compound crosslinked at 10a- and 12-positions | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-10-23 | — | — | US | disclosed |
| US-20120245140-A1 | N-CONTAINING HETEROARYL DERIVATIVES AS JAK3 KINASE INHIBITORS | ALMANSA ROSALES CARMEN (ES) | 2012-09-27 | — | — | US | disclosed |
| WO-2012115256-A1 | C-4\" POSITION SUBSTITUTED MACROLIDE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-08-30 | — | — | WO | disclosed |
| EP-2327692-B1 | 1-heterocyclylsulfonyl, 2-aminomethyl, 5-(hetero-)aryl substituted 1-H-pyrrole derivatives as acid secretion inhibitors | TAKEDA PHARMACEUTICAL (JP) | 2012-07-18 | — | — | EP | disclosed |
| WO-2012087833-A1 | HEPATITIS C INHIBITORS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2012-06-28 | — | — | WO | disclosed |
| US-20120122840-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | MYREXIS, INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120088797-A1 | 1-HETEROCYCLYLSULFONYL, 3-AMINOMETHYL, 5- (HETERO-) ARYL SUBSTITUTED 1-H-PYRROLE DERIVATIVES AS ACID SECRETION INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-04-12 | — | — | US | disclosed |
| US-8124744-B2 | Macrolide derivatives | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-02-28 | — | — | US | disclosed |
| US-8110570-B2 | Modulators of acetyl-coenzyme A carboxylase and methods of use thereof | CROPSOLUTION, INC. (US) | 2012-02-07 | — | — | US | disclosed |
| US-8097708-B2 | 10a-Azalide compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-20110301174-A1 | 1-HETEROCYCLYLSULFONYL, 3-AMINOMETHYL, 5- (HETERO-) ARYL SUBSTITUTED 1-H-PYRROLE DERIVATIVES AS ACID SECRETION INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-12-08 | — | — | US | disclosed |
| US-20110301173-A1 | 1-HETEROCYCLYLSULFONYL, 3-AMINOMETHYL, 5- (HETERO-) ARYL SUBSTITUTED 1-H-PYRROLE DERIVATIVES AS ACID SECRETION INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-12-08 | — | — | US | disclosed |
| US-8048909-B2 | Proton pump inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-11-01 | — | — | US | disclosed |
| US-20110237784-A1 | 10A-AZALIDE COMPOUND CROSSLINKED AT 10A- AND 12-POSITIONS | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-09-29 | — | — | US | disclosed |
| US-8017780-B1 | Therapeutic compounds and uses thereof | MYREXIS, INC. (US) | 2011-09-13 | — | — | US | disclosed |
| US-7977488-B2 | 1-heterocyclylsulfonyl, 2-aminomethyl, 5-(hetero-) aryl substituted 1-H-pyrrole derivatives as acid secretion inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-07-12 | — | — | US | disclosed |
| WO-2011076878-A1 | AMINOALKYLPYRIMIDINE DERIVATIVES AS HISTAMINE H4 RECEPTOR ANTAGONISTS | PALAU PHARMA, S.A. (ES) | 2011-06-30 | — | — | WO | disclosed |
| US-20110160185-A9 | PYRROLOPYRIMIDINE DERIVATIVES AS JAK3 INHIBITORS | PALAU PHARMA, S.A. (ES) | 2011-06-30 | — | — | US | disclosed |
| US-20110152239-A1 | 10A-AZALIDE COMPOUND HAVING 4-MEMBERED RING STRUCTURE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-06-23 | — | — | US | disclosed |
| EP-2336107-A2 | Proton pump inhibitors | Takeda Pharmaceutical Company Limited (JP) | 2011-06-22 | — | — | EP | disclosed |
| US-20110144161-A1 | 1-HETEROCYCLYLSULFONYL, 2-AMINOMETHYL, 5- (HETERO-) ARYL SUBSTITUTED 1-H-PYRROLE DERIVATIVES AS ACID SECRETION INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-06-16 | — | — | US | disclosed |
| EP-2327692-A1 | 1-heterocyclylsulfonyl, 2-aminomethyl, 5-(hetero-)aryl substituted 1-H-pyrrole derivatives as acid secretion inhibitors | Takeda Pharmaceutical Company Limited (JP) | 2011-06-01 | — | — | EP | disclosed |
| US-20110124687-A1 | PHARMACEUTICAL COMPOSITION | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-26 | — | — | US | disclosed |
| EP-2310015-A1 | MODULATORS OF ACETYL-COENZYME A CARBOXYLASE AND METHODS OF USE THEREOF | Cropsolution, Inc. (US) | 2011-04-20 | — | — | EP | disclosed |
| EP-1919865-B1 | 1-HETEROCYCLYLSULFONYL, 2-AMINOMETHYL, 5- (HETERO-) ARYL SUBSTITUTED 1-H-PYRROLE DERIVATIVES AS ACID SECRETION INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2011-04-06 | — | — | EP | disclosed |
| EP-2287173-A1 | 10A-AZALIDE COMPOUND HAVING 4-MEMBERED RING STRUCTURE | Taisho Pharmaceutical Co., Ltd. (JP) | 2011-02-23 | — | — | EP | disclosed |
| US-20110028476-A1 | PROTON PUMP INHIBITORS | KAJINO MASAHIRO | 2011-02-03 | — | — | US | disclosed |
| US-20110009444-A1 | N-AZABICYCLIC CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-01-13 | — | — | US | disclosed |
| US-20100292255-A1 | Therapeutic Compounds and Their Use in Treating Diseases and Disorders | MYRIAD PHARMACEUTICALS, INC. (US) | 2010-11-18 | — | — | US | disclosed |
| EP-2235016-A1 | AZABICYCLIC CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2010-10-06 | — | — | EP | disclosed |
| US-20100240630-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | Myriad Pharmaceuticals, Inc.. (US) | 2010-09-23 | — | — | US | disclosed |
| US-20100222363-A1 | Bicyclic Derivatives as P38 Inhibitors | PALAU PHARMA, S.A. (ES) | 2010-09-02 | — | — | US | disclosed |
| US-20100204187-A1 | Purine Derivatives | PALAU PHARMA, S.A. (ES) | 2010-08-12 | — | — | US | disclosed |
| WO-2010072823-A1 | PYRAZOLE[1,5a]PYRIDINE DERIVATIVES | PALAU PHARMA, S. A. (ES) | 2010-07-01 | — | — | WO | disclosed |
| US-20100113420-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS JAK3 INHIBITORS | PALAU PHARMA, S.A. (ES) | 2010-05-06 | — | — | US | disclosed |
| EP-2177526-A1 | 10A-AZALIDE COMPOUND CROSSLINKED AT POSITION-10A AND POSITION-12 | Taisho Pharmaceutical Co. Ltd. (JP) | 2010-04-21 | — | — | EP | disclosed |
| WO-2010034740-A1 | (R)-3-(N,N-DIMETHYLAMINO)PYRROLIDINE DERIVATIVES | PALAU PHARMA, S.A. (ES) | 2010-04-01 | — | — | WO | disclosed |
| US-20100048543-A1 | PYRIMIDINE COMPOUNDS HAVING TIES (TEK) INHIBITORY ACTIVITY | ASTRAZENECA AB (SE) | 2010-02-25 | — | — | US | disclosed |
| WO-2010008521-A1 | MODULATORS OF ACETYL-COENZYME A CARBOXYLASE AND METHODS OF USE THEREOF | CROPSOLUTION, INC. (US) | 2010-01-21 | — | — | WO | disclosed |
| US-20100009982-A1 | Modulators of Acetyl-Coenzyme A Carboxylase and Methods of Use Thereof | CROPSOLUTION, INC. | 2010-01-14 | — | — | US | disclosed |
| EP-2142550-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS JAK3 INHIBITORS | Palau Pharma, S.A. (ES) | 2010-01-13 | — | — | EP | disclosed |
| US-20090286775-A1 | Bicyclic Derivatives as P38 Kinase Inhibitors | PALAU PHARMA, S.A. (ES) | 2009-11-19 | — | — | US | disclosed |
| EP-2118105-A1 | PURINE DERIVATIVES | Palau Pharma, S.A. (ES) | 2009-11-18 | — | — | EP | disclosed |
| US-20090281292-A1 | 10a-Azalide Compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
| US-20090275591-A1 | 1-HETEROCYCLYLSULFONYL, 2-AMINOMETHYL, 5- (HETERO-) ARYL SUBSTITUTED 1-H-PYRROLE DERIVATIVES AS ACID SECRETION INHIBITOR | TAKEDA PHARMACEUTICAL COMPANY LIMTED (JP) | 2009-11-05 | — | — | US | disclosed |
| US-20090264446-A9 | Condensed Pyridines as Kinase Inhibitors | PALAU PHARMA, S.A. (ES) | 2009-10-22 | — | — | US | disclosed |
| WO-2009112679-A1 | AZABICYCLIC CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2009-09-17 | — | — | WO | disclosed |
| US-20090143444-A1 | ACID SECRETION INHIBITOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-04 | — | — | US | disclosed |
| US-20090076253-A1 | MACROLIDE DERIVATIVES | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2009-03-19 | — | — | US | disclosed |
| US-7498337-B2 | Acid secretion inhibitor | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-03-03 | — | — | US | disclosed |
| US-20080318977-A1 | Condensed Pyridines as Kinase Inhibitors | PALAU PHARMA, S.A. (ES) | 2008-12-25 | — | — | US | disclosed |
| US-20080312435-A1 | Imine Compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2008-12-18 | — | — | US | disclosed |
| EP-1737463-B1 | PYRIMIDINES WITH TIE2 (TEK) ACTIVITY | ASTRAZENECA AB (SE) | 2008-12-03 | — | — | EP | disclosed |
| US-20080269209-A1 | Pyrazoloisoquinoline Derivatives | PALAU PHARMA, S.A. (ES) | 2008-10-30 | — | — | US | disclosed |
| EP-1985620-A1 | 10a-AZALIDE COMPOUND | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2008-10-29 | — | — | EP | disclosed |
| WO-2008119792-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS JAK3 INHIBITORS | PALAU PHARMA, S. A. (ES) | 2008-10-09 | — | — | WO | disclosed |
| EP-1960400-A1 | PYRAZOLOISOQUINOLINE DERIVATIVES | Palau Pharma, S.A. (ES) | 2008-08-27 | — | — | EP | disclosed |
| US-20080194552-A1 | Aminopyrimidine Derivatives With Tie2 Inhibiting Activity | ASTRAZENECA AB (SE) | 2008-08-14 | — | — | US | disclosed |
| WO-2008090181-A1 | PURINE DERIVATIVES | PALAU PHARMA, S. A. (ES) | 2008-07-31 | — | — | WO | disclosed |
| EP-1737462-B1 | PYRIMIDINES WITH TIE2 (TEK) ACTIVITY | ASTRAZENECA AB (SE) | 2008-07-30 | — | — | EP | disclosed |
| US-20080153838-A1 | Compounds Having Tie2 (Tek) Activity | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | US | disclosed |
| US-20080146599-A1 | Pyrimidine Compounds Having Tie-2 (Tek) Inhibitory Activity | ASTRAZENECA AB (SE) | 2008-06-19 | — | — | US | disclosed |
| US-20080139639-A1 | 3-amino(alkyl)-substituted pyrrole compounds such as N-methyl-1-[1-(phenylsulfonyl)-5-(3-thienyl)-1H-pyrrol-3-yl]methanamine; peptic ulcer, Zollinger-Ellison syndrome, gastritis, gastroesophageal reflux disease, gastric cancer, ulcer caused by non-steroidal anti-inflammatory agent (NSAID) use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-06-12 | — | — | US | disclosed |
| US-20080108608-A1 | Pyrimidines With Tie2 (Tek) Activity | ASTRAZENECA AB (SE) | 2008-05-08 | — | — | US | disclosed |
| EP-1917241-A2 | BICYCLIC DERIVATIVES AS P38 KINASE INHIBITORS | Palau Pharma, S.A. (ES) | 2008-05-07 | — | — | EP | disclosed |
| EP-1907358-A2 | BICYCLIC DERIVATIVES AS P38 KINASE INHIBITORS | Palau Pharma, S.A. (ES) | 2008-04-09 | — | — | EP | disclosed |
| US-20080027076-A1 | Pyrimidines With Tie2 (Tek) Activity | ASTRAZENECA AB (SE) | 2008-01-31 | — | — | US | disclosed |
| EP-1863805-A1 | PYRIMIDINE COMPOUNDS HAVING TIE2 (TEK) INHIBITORY ACTIVITY | AstraZeneca AB (SE) | 2007-12-12 | — | — | EP | disclosed |
| EP-1848715-A1 | COMPOUNDS HAVING TIE2 (TEK) INHIBITORY ACTIVITY | AstraZeneca AB (SE) | 2007-10-31 | — | — | EP | disclosed |
| EP-1846399-A1 | PYRIMIDINE COMPOUNDS HAVING TIE2 (TEK) INHIBITORY ACTIVITY | AstraZeneca AB (SE) | 2007-10-24 | — | — | EP | disclosed |
| EP-1833828-A2 | CONDENSED PYRIDINES AS KINASE INHIBITORS | Palau Pharma, S.A. (ES) | 2007-09-19 | — | — | EP | disclosed |
| EP-1820504-A1 | IMINE COMPOUND | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2007-08-22 | — | — | EP | disclosed |
| EP-1803709-A1 | PROTON PUMP INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2007-07-04 | — | — | EP | disclosed |
| WO-2007060198-A1 | PYRAZOLOISOQUINOLINE DERIVATIVES | PALAU PHARMA, S. A. (ES) | 2007-05-31 | — | — | WO | disclosed |
| US-20070060623-A1 | antiulcer agents; proton pump inhibitors; side effect reduction; 1-[4-fluoro-5-phenyl-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine; superior acid secretion inhibitory effect; peptic ulcer, Zollinger-Ellison syndrome, reflux esophagitis, or symptomatic gastroesophageal reflux disease | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-03-15 | — | — | US | disclosed |
| WO-2007000337-A1 | BICYCLIC DERIVATIVES AS P38 KINASE INHIBITORS | PALAU PHARMA, S.A. (ES) | 2007-01-04 | — | — | WO | disclosed |
| WO-2007000339-A1 | BICYCLIC DERIVATIVES AS P38 KINASE INHIBITORS | PALAU PHARMA, S.A. (ES) | 2007-01-04 | — | — | WO | disclosed |
| WO-2007000340-A2 | BICYCLIC DERIVATIVES AS P38 KINASE INHIBITORS | PALAU PHARMA, S.A. (ES) | 2007-01-04 | — | — | WO | disclosed |
| EP-1737463-A1 | PYRIMIDINES WITH TIE2 (TEK) ACTIVITY | AstraZeneca AB (SE) | 2007-01-03 | — | — | EP | disclosed |
| EP-1737462-A1 | PYRIMIDINES WITH TIE2 (TEK) ACTIVITY | AstraZeneca AB (SE) | 2007-01-03 | — | — | EP | disclosed |
| WO-2006082373-A1 | PYRIMIDINE COMPOUNDS HAVING TIES (TEK) INHIBITORY ACTIVITY | ASTRAZENECA AB (SE) | 2006-08-10 | — | — | WO | disclosed |
| WO-2006082371-A1 | PYRIMIDINE COMPOUNDS HAVING TIE2 (TEK) INHIBITORY ACTIVITY | ASTRAZENECA AB (SE) | 2006-08-10 | — | — | WO | disclosed |
| WO-2006082404-A1 | COMPOUNDS HAVING TIE2 (TEK) INHIBITORY ACTIVITY | ASTRAZENECA AB (SE) | 2006-08-10 | — | — | WO | disclosed |
| WO-2006013095-A2 | CONDENSED PYRIDINES AS KINASE INHIBITORS | PALAU PHARMA, S.A. (ES) | 2006-02-09 | — | — | WO | disclosed |
| WO-2005060969-A1 | PYRIMIDINES WITH TIE2 (TEK) ACTIVITY | ASTRAZENECA AB (SE) | 2005-07-07 | — | — | WO | disclosed |
| WO-2005060969-A1 | PYRIMIDINES WITH TIE2 (TEK) ACTIVITY | ASTRAZENECA AB (SE) | 2005-07-07 | — | — | WO | disclosed |
| WO-2005060970-A1 | PYRIMIDINES WITH TIE2 (TEK) ACTIVITY | ASTRAZENECA AB (SE) | 2005-07-07 | — | — | WO | disclosed |